A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
Status:
Recruiting
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test whether the combination of lenvatinib, pembrolizumab,
and fulvestrant is a safe and effective treatment that causes few or mild side effects in
people with ER+/HER2- metastatic breast cancer.